Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+prostate cancer stem cells by flavopiridol

International Journal of Molecular Medicine

Volumn 34, Issue 5, 2014, Pages 1249-1256

  Soner, Burak Cem ^a   Aktug, Huseyin ^b   Acikgoz, Eda ^b   Duzagac, Fahriye ^c   Guven, Ummu ^c   Ayla, Sule ^d   Cal, Cag ^e   Oktem, Gulperi ^b  

^a NECMETTIN ERBAKAN UNIVERSITY   (Turkey)

^b EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c EGE UNIVERSITY   (Turkey)

^d Zeynep Kamil Gynecology and Pediatrics Training and Research Hospital   (Turkey)

^e IZMIR UNIVERSITY OF ECONOMICS   (Turkey)

Author keywords

Apoptosis; Flavopiridol; Prostate cancer; Stem cell

Indexed keywords

CASPASE 3; CASPASE 8; CD133 ANTIGEN; CD44V ANTIGEN; FLAVOPIRIDOL; LIPOCORTIN 5; PROTEIN P53; CASP3 PROTEIN, HUMAN; CASP8 PROTEIN, HUMAN; FLAVONOID; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; PIPERIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER STEM CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IC50; IMMUNOFLUORESCENCE; MALE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; TUMOR SPHEROID; CELL CYCLE CHECKPOINT; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

ANTIGENS, CD; APOPTOSIS; CASPASE 3; CASPASE 8; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; GLYCOPROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; NEOPLASTIC STEM CELLS; PEPTIDES; PIPERIDINES; PROSTATE; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84907189766     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1930     Document Type: Article

References (30)

1. Naik RG, Kattige SL, Bhat SV, Alreja B, de Souza NJ and Rupp RH: An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from dysoxylum binectariferum: isolation, structure and total synthesis. Tetrahedron 44: 2081-2086, 1988.
2. Newcomb EW, Tamasdan C, Entzminger Y, et al: Flavopiridol induces mitochondrial-mediated apoptosis in murine glioma GL261 cells via release of cytochrome c and apoptosis inducing factor. Cell Cycle 2: 243-250, 2003.
3. Grant S and Dent P: Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what's in a name? Mol Cancer Ther 3: 873-875, 2004.
4. Knig A, Schwartz GK, Mohammad RM, AlKatib A and Gabrilove JL: The novel cyclindependent kinase inhibitor flavopiridol downregulates Bcl2 and induces growth arrest and apoptosis in chronic B cell leukemia lines. Blood 90: 4307-4312, 1997.
5. Hooijberg JH, Broxterman HJ, Scheffer GL, et al: Potent interaction of flavopiridol with MRP1. Br J Cancer 81: 269-276, 1999.
6. Cimica V, Smith ME, Zhang Z, Mathur D, Mani S and Kalpana GV: Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen. BMC Cancer 10: 634, 2010.
7. Chen R, Keating MJ, Gandhi V and Plunkett W: Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106: 2513-2519, 2005.
8. Senderowicz AM: Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 17: 313-320, 1999.
9. Stadler WM, Vogelzang NJ, Amato R, et al: Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study. J Clin Oncol 18: 371-375, 2000.
10. Budak-Alpdogan T, Chen B, Warrier A, Medina DJ, Moore D and Bertino JR: Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma. Clin Cancer Res 15: 1232-1240, 2009.
11. Meacham CE and Morrison SJ: Tumour heterogeneity and cancer cell plasticity. Nature 501: 328-337, 2013.
12. Kreso A and Dick JE: Evolution of the cancer stem cell model. Cell Stem Cell 14: 275-291, 2014.
13. La Porta CA: Mechanism of drug sensitivity and resistance in melanoma. Curr Cancer Drug Targets 9: 391-397, 2009.
14. Goksel G, Bilir A, Uslu R, Akbulut H, Guven U and Oktem G: WNT1 gene expression alters in heterogeneous population of prostate cancer cells; decreased expression pattern observed in CD133+/CD44+ prostate cancer stem cell spheroids. J BUON 19: 207-214, 2014.
15. Oktem G, Bilir A, Uslu R, Inan SV, Demiray SB, Atmaca H, Ayla S, Sercan O and Uysal A: Expression profiling of stem cell signaling alters with spheroid formation in CD133high/CD44high prostate cancer stem cells. Oncol Lett 7: 2103-2109, 2014.
16. Ayla S, Bilir A, Soner BC, Yilmaz-Dilsiz O, Erguven M and Oktem G: Notch signaling-related therapeutic strategies with novel drugs in neuroblastoma spheroids. J Pediatr Hematol Oncol 36: 37-44, 2014.
17. Wirger A, Perabo FG, Burgemeister S, et al: Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. Anticancer Res 25: 4341-4347, 2005.
18. Chien M, Astumian M, Liebowitz D, Rinker-Schaeffer C and Stadler WM: In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother Pharmacol 44: 81-87, 1999.
19. Nelson DM, Joseph B, Hillion J, Segal J, Karp JE and Resar LM: Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk Lymphoma 52: 1999-2006, 2011.
20. Smith ME, Cimica V, Chinni S, Challagulla K, Mani S and Kalpana GV: Rhabdoid tumor growth is inhibited by flavopiridol. Clin Cancer Res 14: 523-532, 2008.
21. Mayer F, Mueller S, Malenke E, Kuczyk M, Hartmann JT and Bokemeyer C: Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines. Invest New Drugs 23: 205-211, 2005.
22. Taniai M, Grambihler A, Higuchi H, et al: Mclß1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 64: 3517-3524, 2004.
23. Decker RH, Dai Y and Grant S: The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ 8: 715-724, 2001.
24. Villela L and Bolaños-Meade J: Acute myeloid leukaemia: optimal management and recent developments. Drugs 71: 1537-1550, 2011.
25. Lamb R, Lehn S, Rogerson L, Clarke RB and Landberg G: Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity. Cell Cycle 12: 2384-2394, 2013.
26. Yao Y, Shi J, Zhang Z, Zhang F, Ma R and Zhao Y: The radiation-sensitizing effect of flavopiridol in the esophageal cancer cell line Eca109. Oncol Lett 5: 1872-1876, 2013.
27. Chao SH, Fujinaga K, Marion JE, et al: Flavopiridol inhibits P-TEFb and blocks HIVß1 replication. J Biol Chem 275: 28345-28348, 2000.
28. Carlson B, Lahusen T, Singh S, et al: Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 59: 4634-4641, 1999.
29. Chao SH and Price DH: Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 276: 31793-31799, 2001.
30. de Azevedo WF Jr, Canduri F and da Silveira NJ: Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun 293: 566-571, 2002.